Literature DB >> 26667590

Intravascular Ultrasound Guidance vs. Angiographic Guidance in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction - Long-Term Clinical Outcomes From the CREDO-Kyoto AMI Registry.

Kenji Nakatsuma1, Hiroki Shiomi, Takeshi Morimoto, Kenji Ando, Kazushige Kadota, Hiroki Watanabe, Tomohiko Taniguchi, Takashi Yamamoto, Yutaka Furukawa, Yoshihisa Nakagawa, Minoru Horie, Takeshi Kimura.   

Abstract

BACKGROUND: In the setting of elective percutaneous coronary intervention (PCI), intravascular ultrasound (IVUS)-guided PCI is associated with a reduction in the incidence of target vessel revascularization (TVR), but the impact of IVUS on long-term clinical outcome in the setting of emergency PCI for ST-segment elevation acute myocardial infarction (STEMI) is still unclear. METHODS AND 
RESULTS: The subjects consisted of 3,028 STEMI patients who underwent primary PCI within 24 h of symptom onset in the CREDO-Kyoto acute myocardial infarction registry. Of these, 932 patients (31%) underwent IVUS-guided PCI. Compared with the angiography-guided PCI without IVUS, IVUS-guided PCI was associated with significantly lower incidences of TVR (primary outcome measure; 22% vs. 27%, log-rank P<0.001) and definite stent thrombosis (ST; 1.2% vs. 3.1%, log-rank P=0.003). The cumulative incidence of all-cause death was not significantly different between the 2 groups. After adjusting for confounders, however, there were no significant differences between the 2 groups in risk for TVR (adjusted HR, 1.14; 95% CI: 0.86-1.51, P=0.38) and definite ST (adjusted HR, 0.58; 95% CI: 0.19-1.72, P=0.33).
CONCLUSIONS: IVUS-guided PCI was not associated with a lower risk for TVR or ST in STEMI patients undergoing primary PCI.

Entities:  

Mesh:

Year:  2015        PMID: 26667590     DOI: 10.1253/circj.CJ-15-0870

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

1.  Frequency and prognostic impact of intravascular imaging-guided urgent percutaneous coronary intervention in patients with acute myocardial infarction: results from J-MINUET.

Authors:  Hiroyuki Okura; Yoshihiko Saito; Tsunenari Soeda; Koichi Nakao; Yukio Ozaki; Kazuo Kimura; Junya Ako; Teruo Noguchi; Satoshi Yasuda; Satoru Suwa; Kazuteru Fujimoto; Yasuharu Nakama; Takashi Morita; Wataru Shimizu; Atsushi Hirohata; Yasuhiro Morita; Teruo Inoue; Atsunori Okamura; Masaaki Uematsu; Kazuhito Hirata; Kengo Tanabe; Yoshisato Shibata; Mafumi Owa; Kenichi Tsujita; Kunihiro Nishimura; Yoshihiro Miyamoto; Masaharu Ishihara
Journal:  Heart Vessels       Date:  2018-11-02       Impact factor: 2.037

2.  Intravascular ultrasound versus angiography-guided, drug-eluting stent implantation: A meta-analysis of randomised control trials and systematic review. Data from registries in a meta-analysis of randomised control trials.

Authors:  Ashish Kumar; Mariam Shariff
Journal:  Int Wound J       Date:  2019-06-18       Impact factor: 3.315

3.  Real-world use of intravascular ultrasound in Japan: a report from contemporary multicenter PCI registry.

Authors:  Toshiki Kuno; Yohei Numasawa; Mitsuaki Sawano; Takayuki Abe; Ikuko Ueda; Masaki Kodaira; Masahiro Suzuki; Shigetaka Noma; Iwao Nakamura; Koji Negishi; Shiro Ishikawa; Keiichi Fukuda; Shun Kohsaka
Journal:  Heart Vessels       Date:  2019-05-25       Impact factor: 2.037

4.  Comparison of clinical outcomes between intravascular ultrasound-guided and angiography-guided drug-eluting stent implantation: A meta-analysis of randomised control trials and systematic review.

Authors:  Yu-Ying Tan; Xia-Xia Man; Ling-Yun Liu; Hui Xu
Journal:  Int Wound J       Date:  2019-01-30       Impact factor: 3.315

5.  Long-Term Efficacy and Safety of Everolimus-Eluting Stent Implantation in Japanese Patients with Acute Coronary Syndrome: Five-Year Real-World Data from the Tokyo-MD PCI Study.

Authors:  Shunji Yoshikawa; Takashi Ashikaga; Toru Miyazaki; Ken Kurihara; Kenzo Hirao
Journal:  J Interv Cardiol       Date:  2019-11-03       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.